Parkinson's disease (PD) is a prevalent neurodegenerative disorder known for its impact on motor neurons, causing symptoms like tremors, stiffness, and gait difficulties. This study explores the potential of vocal feature alterations in PD patients as a means of early disease prediction. This research aims to predict the onset of Parkinson's disease. Utilizing a variety of advanced machine-learning algorithms, including XGBoost, LightGBM, Bagging, AdaBoost, and Support Vector Machine, among others, the study evaluates the predictive performance of these models using metrics such as accuracy, area under the curve (AUC), sensitivity, and specificity. The findings of this comprehensive analysis highlight LightGBM as the most effective model, achieving an impressive accuracy rate of 96% alongside a matching AUC of 96%. LightGBM exhibited a remarkable sensitivity of 100% and specificity of 94.43%, surpassing other machine learning algorithms in accuracy and AUC scores. Given the complexities of Parkinson's disease and its challenges in early diagnosis, this study underscores the significance of leveraging vocal biomarkers coupled with advanced machine-learning techniques for precise and timely PD detection.

Machine learning represents a growing subfield of artificial intelligence with much promise in the diagnosis, treatment, and tracking of complex conditions, including neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. While no definitive methods of diagnosis or treatment exist for either disease, researchers have implemented machine learning algorithms with neuroimaging and motion-tracking technology to analyze pathologically relevant symptoms and biomarkers. Deep learning algorithms such as neural networks and complex combined architectures have proven capable of tracking disease-linked changes in brain structure and physiology as well as patient motor and cognitive symptoms and responses to treatment. However, such techniques require further development aimed at improving transparency, adaptability, and reproducibility. In this review, we provide an overview of existing neuroimaging technologies and supervised and unsupervised machine learning techniques with their current applications in the context of Alzheimer's and Parkinson's diseases.

A research group from Nagoya University in Japan has developed an artificial intelligence for analyzing cell images that uses machine learning to predict the therapeutic effect of drugs. Called in silico FOCUS, this new technology may aid in the discovery of therapeutic agents for neurodegenerative disorders such as Kennedy disease. Current treatments for neurodegenerative diseases often have harsh side effects, including sexual dysfunction and blocking muscle tissue formation. However, researchers searching for new, less harmful treatments have been hindered by the lack of effective screening technologies to discern whether a drug is effective. One promising concept is the'anomaly discrimination concept', meaning neurons that respond to treatment have slight differences in shape compared to those that do not.

The new research from the University of Sheffield's Neuroscience Institute examines how the routine use of AI in healthcare could help to relieve the time and economic impact that common neurodegenerative diseases, such as Alzheimer's and Parkinson's, put on the NHS. The main risk factor for many neurological disorders is age, and with populations worldwide living longer than ever before, the number of people with a neurodegenerative disease is expected to hit unprecedented levels. The number of people living with Alzheimer's alone is predicted to treble to 115 million by 2050, posing a real challenge for the health system. The new study, published in the journal Nature Reviews Neurology, highlights how AI technologies, such as machine learning algorithms, can detect neurodegenerative disorders -- which cause part of the brain to die -- before progressive symptoms worsen. This can improve patients' chances of benefitting from successful disease-modifying treatment.

A revolutionary lightweight exosuit that makes walking and running easier has been developed. Scientists say their pioneering design - weighing just five kilos (11 lbs) - could be worn by soldiers, firefighters or rescue workers. They say it could help keep them fresh by lightening the load of their jobs and assist them in negotiating difficult terrain. The portable gear may also improve mobility and quality of life for the elderly and people suffering from neurodegenerative disorders. A revolutionary lightweight exosuit (pictured) that makes walking and running easier has been developed.

SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets. Errol De Souza, President and CEO of Neuropore, stated, "We are very excited to establish this collaboration with BenevolentAI. The application of artificial intelligence to the elaboration of novel approaches to medicine is one of the leading edges of science and is an approach that is bound to lead to new discoveries. Neuropore's Autophagy Platform is a perfect testing ground for new hypotheses and discoveries. In addition to its drug discovery capabilities, Neuropore's development and translational experience in degenerative disease makes it a great fit for both companies."

There might be a lot of hype around what machine learning and artificial intelligence can do for healthcare, but a new study could showcase the real-life potential of the technology for early disease detection. The study, conducted by Microsoft and Duke University and published in late April in Nature's npj Digital Medicine, showcases the power of trained machine learning models to automatically detect neurodegenerative disorders by using information from patient interactions with search engines. The research is specific to Parkinson's disease but could be adapted to fit similar neurodegenerative disorders, such as Alzheimer's disease. SIGN UP: Get more news from the HealthTech newsletter in your inbox every two weeks! With Parkinson's disease impacting nearly 1 percent of people over age 60, it is the second-most prevalent neurodegenerative disorder, the researcher authors note in the study's abstract.